Successful eradication of de novo HLA antibodies with daratumumab in immune-mediated cytopenias after allogeneic stem cell transplantation: a case report

IF 2.3 3区 医学 Q2 HEMATOLOGY
Annals of Hematology Pub Date : 2026-07-15 Epub Date: 2026-08-17 DOI:10.1007/s00277-026-07150-6
Xianfu Sheng, Tonglin Hu, Hangping Ge, Huijin Hu, Linlin Huang, Baodong Ye, Yu Zhang
{"title":"Successful eradication of de novo HLA antibodies with daratumumab in immune-mediated cytopenias after allogeneic stem cell transplantation: a case report","authors":"Xianfu Sheng,&nbsp;Tonglin Hu,&nbsp;Hangping Ge,&nbsp;Huijin Hu,&nbsp;Linlin Huang,&nbsp;Baodong Ye,&nbsp;Yu Zhang","doi":"10.1007/s00277-026-07150-6","DOIUrl":null,"url":null,"abstract":"<div><p>Refractory immune-mediated cytopenias (IMCs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are a challenging complication with limited therapeutic options. Although preexisting human leukocyte antigen (HLA) antibodies, particularly donor-specific antibodies (DSAs), are well-established risk factors for graft failure, the clinical significance and mechanistic role of de novo HLA antibodies emerging after transplantation remain poorly defined. Whether such antibodies are associated with posttransplant IMCs has not been systematically explored. We report two patients with severe aplastic anemia who developed refractory IMCs after allo-HSCT in association with high-titer de novo HLA antibodies and preserved full donor chimerism. In case 1, combined HLA class I and II antibodies were detected in association with trilineage cytopenia. Rituximab, corticosteroids and plasma exchange reduced HLA class II antibodies (including DSAs), whereas persistent HLA class I antibodies were linked to ongoing pancytopenia despite multi-agent treatment. In case 2, isolated high-titer de novo HLA class II antibodies were detected in association with late-onset thrombocytopenia, refractory to corticosteroids and rituximab. In both patients, plasma cell–directed therapy with daratumumab led to definitive clearance of de novo HLA antibodies and was followed by rapid and sustained hematologic recovery, including coordinated trilineage recovery in case 1 and selective platelet recovery in case 2. These cases provide initial hypothesis-generating observations that de novo HLA antibodies are associated with and may contribute to refractory IMCs after allo-HSCT. The concordance across antibody class, lineage-specific or multilineage hematopoietic injury, and lineage-matched recovery after antibody clearance suggests a functional immunophenotype–hematopoietic phenotype coupling that warrants further investigation.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 9","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07150-6.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-026-07150-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Refractory immune-mediated cytopenias (IMCs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are a challenging complication with limited therapeutic options. Although preexisting human leukocyte antigen (HLA) antibodies, particularly donor-specific antibodies (DSAs), are well-established risk factors for graft failure, the clinical significance and mechanistic role of de novo HLA antibodies emerging after transplantation remain poorly defined. Whether such antibodies are associated with posttransplant IMCs has not been systematically explored. We report two patients with severe aplastic anemia who developed refractory IMCs after allo-HSCT in association with high-titer de novo HLA antibodies and preserved full donor chimerism. In case 1, combined HLA class I and II antibodies were detected in association with trilineage cytopenia. Rituximab, corticosteroids and plasma exchange reduced HLA class II antibodies (including DSAs), whereas persistent HLA class I antibodies were linked to ongoing pancytopenia despite multi-agent treatment. In case 2, isolated high-titer de novo HLA class II antibodies were detected in association with late-onset thrombocytopenia, refractory to corticosteroids and rituximab. In both patients, plasma cell–directed therapy with daratumumab led to definitive clearance of de novo HLA antibodies and was followed by rapid and sustained hematologic recovery, including coordinated trilineage recovery in case 1 and selective platelet recovery in case 2. These cases provide initial hypothesis-generating observations that de novo HLA antibodies are associated with and may contribute to refractory IMCs after allo-HSCT. The concordance across antibody class, lineage-specific or multilineage hematopoietic injury, and lineage-matched recovery after antibody clearance suggests a functional immunophenotype–hematopoietic phenotype coupling that warrants further investigation.

在异基因干细胞移植后免疫介导的细胞减少症中,达拉图单抗成功根除新生HLA抗体:1例报告。
同种异体造血干细胞移植(alloo - hsct)后的难治性免疫介导性细胞减少症(IMCs)是一个具有挑战性的并发症,治疗方案有限。虽然先前存在的人类白细胞抗原(HLA)抗体,特别是供体特异性抗体(dsa),是移植失败的公认危险因素,但移植后出现的新HLA抗体的临床意义和机制作用仍然不明确。这些抗体是否与移植后IMCs相关还没有系统的探讨。我们报告了两例严重再生障碍性贫血患者,他们在同种异体造血干细胞移植后出现难治性IMCs,并伴有高滴度的新生HLA抗体和保存完整的供体嵌合。在病例1中,检测到HLA I类和II类联合抗体与三岁期细胞减少症有关。利妥昔单抗、皮质类固醇和血浆交换降低了HLA II类抗体(包括dsa),而尽管多药治疗,持续的HLA I类抗体仍与持续的全血细胞减少症有关。在病例2中,分离的高滴度新生HLA II类抗体被检测到与迟发性血小板减少症有关,对皮质类固醇和利妥昔单抗有难治性。在这两例患者中,使用daratumumab的血浆细胞定向治疗导致了新生HLA抗体的明确清除,随后是快速和持续的血液学恢复,包括病例1的协调三龄恢复和病例2的选择性血小板恢复。这些病例提供了初步的假设生成观察结果,即新生HLA抗体与异体造血干细胞移植后难治性IMCs相关,并可能导致这些IMCs。抗体类别、谱系特异性或多谱系造血损伤以及抗体清除后谱系匹配恢复之间的一致性表明,功能性免疫表型-造血表型耦合值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书